| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC2623 |
| Trial ID | NCT04796688 |
| Disease | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | B-Cell Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-NK cell |
| Treatment | AT19 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies |
| Year | 2021 |
| Country | China |
| Company sponsor | Wuhan Union Hospital, China |
| Other ID(s) | Universal AT19 cells |
| Cohort 1 | |||||||||||||
|
|||||||||||||